Impact of HMG-CoA reductase inhibitor (statin) use on blood loss during robot-assisted and open radical prostatectomy

Journal of Endourology

Volumn 25, Issue 9, 2011, Pages 1427-1433

  Truesdale, Matthew D ^a   Polland, Allison R ^a   Graversen, Joseph A ^a   Sartori, Samantha ^b   Hruby, Gregory W ^a   Landman, Jaime ^a   McKiernan, James M ^a   Benson, Mitchell C ^a   Badani, Ketan K ^a  

^a Department of Medicine   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD CLOTTING; COMPUTER ASSISTED SURGERY; CONTROLLED STUDY; GLEASON SCORE; HEMATOCRIT; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COUNSELING; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATECTOMY; RETROSPECTIVE STUDY; ROBOT ASSISTED SURGERY; ROBOTICS; THROMBOSIS; TREATMENT PLANNING;

BLOOD LOSS, SURGICAL; COHORT STUDIES; DEMOGRAPHY; HEMATOCRIT; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PROSTATECTOMY; ROBOTICS;

EID: 80052613478     PISSN: 08927790     EISSN: 1557900X     Source Type: Journal    
DOI: 10.1089/end.2010.0688     Document Type: Article

References (34)

1. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: Systematic review and metaanalysis. BMJ 2003;326:1423.
2. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials. JAMA 1999;282:2340-2346. (Pubitemid 30013066)
3. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004;109(suppl 1):III39-III43. (Pubitemid 38786442)
4. Wainwright CL. Statins-is there no end to their usefulness? Cardiovasc Res 2005;65:296-298. (Pubitemid 40082469)
5. Ray JG, Mamdani M, Tsuyuki RT, et al. Use of statins and the subsequent development of deep vein thrombosis. Arch Intern Med 2001;161:1405-1410. (Pubitemid 32681161)
6. Yang CC, Jick SS, Jick H. Statins and the risk of idiopathic venous thromboembolism. Br J Clin Pharmacol 2002;53: 101-105. (Pubitemid 34117746)
7. Agarwal V, Phung OJ, Tongbram V, et al. Statin use and the prevention of venous thromboembolism: A meta-analysis. Int J Clin Pract. 2010;64:1375-83.
8. Hindler K, Shaw AD, Samuels J, et al. Improved postoperative outcomes associated with preoperative statin therapy. Anesthesiology 2006;105:1260-1272. (Pubitemid 44808591)
9. Hauer-Jensen M, Fort C, Mehta JL, Fink LM. Influence of statins on postoperative wound complications after inguinal or ventral herniorrhaphy. Hernia 2006;10:48-52.
10. Mitka M. Expanding statin use to help more at-risk patients is causing financial heartburn. JAMA 2003;290:2243-2245. (Pubitemid 37430551)
11. Ma J, Sehgal NL, Ayanian JZ, Stafford RS. National trends in statin use by coronary heart disease risk category. PLoS Med 2005;2:e123.
12. Mann D, Reynolds K, Smith D, Muntner P. Trends in statin use and low-density lipoprotein cholesterol levels among US adults: Impact of the 2001 National Cholesterol Education Program guidelines. Ann Pharmacother 2008; 42:1208-1215.
13. Atsumi T, Khamashta MA, Andujar C, et al. Elevated plasma lipoprotein(a) level and its association with impaired fibrinolysis in patients with antiphospholipid syndrome. J Rheumatol 1998;25:69-73. (Pubitemid 28060120)
14. Bladbjerg EM, Marckmann P, Sandstrom B, Jespersen J. Non-fasting factor VII coagulant activity (FVII:C) increased by high-fat diet. Thromb Haemost 1994;71:755-758. (Pubitemid 24177965)
15. Tan KC, Janus ED, Lam KS. Effects of fluvastatin on prothrombotic and fibrinolytic factors in type 2 diabetes mellitus. Am J Cardiol 1999;84:934-937, A7.
16. Dangas G, Smith DA, Badimon JJ, et al. Gender differences in blood thrombogenicity in hyperlipidemic patients and response to pravastatin. Am J Cardiol 1999;84:639-643. (Pubitemid 29417953)
17. Fenton JW Jr, Shen GX. Statins as cellular antithrombotics. Haemostasis 1999;29:166-169. (Pubitemid 30048407)
18. Menon M, Tewari A, Baize B, et al. Prospective comparison of radical retropubic prostatectomy and robot-assisted anatomic prostatectomy: The Vattikuti Urology Institute experience. Urology 2002;60:864-868. (Pubitemid 35300356)
19. Tewari A, Srivasatava A, Menon M. A prospective comparison of radical retropubic and robot-assisted prostatectomy: Experience in one institution. BJU Int 2003;92:205-210. (Pubitemid 36966578)
20. Farnham SB, Webster TM, Herrell SD, Smith JA Jr. Intraoperative blood loss and transfusion requirements for robotic-assisted radical prostatectomy versus radical retropubic prostatectomy. Urology 2006;67:360-363. (Pubitemid 43189856)
21. Fracalanza S, Ficarra V, Cavalleri S, et al. Is robotically assisted laparoscopic radical prostatectomy less invasive than retropubic radical prostatectomy? Results from a prospective, unrandomized, comparative study. BJU Int 2008;101: 1145-1149. (Pubitemid 351502664)
22. Ahlering TE, Woo D, Eichel L, et al. Robot-assisted versus open radical prostatectomy: A comparison of one surgeon's outcomes. Urology 2004;63:819-822. (Pubitemid 38596655)
23. Kordan Y Barocas DA, Altamar HO, et al. Comparison of transfusion requirements between open and robotic-assisted laparoscopic radical prostatectomy. BJU Int 2010;106:1036-1040.
24. Gutt R, Tonlaar N, Kunnavakkam R, et al. Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. J Clin Oncol 2010;28:2653-2659.
25. Jacobs EJ, Rodriguez C, Bain EB, et al. Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U.S. cohort. Cancer Epidemiol Biomarkers Prev 2007;16: 2213-2217. (Pubitemid 351196351)
26. Platz EA, Leitzmann MF, Visvanathan K, et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 2006;98:1819-1825. (Pubitemid 46017933)
27. Shannon J, Tewoderos S, Garzotto M, et al. Statins and prostate cancer risk: A case-control study. Am J Epidemiol 2005;162:318-325. (Pubitemid 41389713)
28. Hamilton RJ, Banez LL, Aronson WJ, et al. Statin medication use and the risk of biochemical recurrence after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer. 2010; 116:3389-3398.
29. Youssef S, Stüve O, Patarroyo JC, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002;420:78-84. (Pubitemid 35291443)
30. Weis M, Heeschen C, Glassford AJ, Cooke JP. Statins have biphasic effects on angiogenesis. Circulation 2002;105: 739-745. (Pubitemid 34157379)
31. Rao S, Porter DC, Chen X, et al. Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl Acad Sci U S A 1999;96:7797-7802. (Pubitemid 29328361)
32. Nübel T, Dippold W, Kleinert H, et al. Lovastatin inhibits Rho-regulated expression of E-selectin by TNFalpha and attenuates tumor cell adhesion. FASEB J 2004;18: 140-142.
33. Kusama T, Mukai M, Iwasaki T, Tet al. Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3- methylglutaryl-coenzyme a reductase inhibitors. Cancer Res 2001;61:4885-4891. (Pubitemid 32691906)
34. Wong WW, Tan MM, Xia Z, et al. Cerivastatin triggers tumor- specific apoptosis with higher efficacy than lovastatin. Clin Cancer Res 2001;7:2067-2075. (Pubitemid 32994846)